Phase II Clinical Trial of Rituximab in Combination With Pegfilgrastim in Patients With Indolent B-Cell (CD-20-Positive) Lymphoma.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Pegfilgrastim (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology